每经AI快讯，2月10日，蔚蓝生物（603739）(603739.SH)公告称，全资子公司蔚蓝生物集团拟与ADM Singapore签署《股权转让协议》，向其购买艾地盟蔚蓝50%股权，交易价格为4700万元。 ...

格隆汇2月10日丨蔚蓝生物(603739.SH)公布，公司董事会于近日收到证券事务代表游淑军先生提交的书 面辞职报告，游淑军先生因个人原因申请辞去公司证券事务代表职务，辞职报告自送达公司董事会之日 起生效。游淑军先生辞职后将不再担任公司任何职务。截至本公告披露日，游淑军先生所负责的工作已 完成交接，其辞职不会影响公司相关工作的开展。 ...

证券日报网讯1月20日，蔚蓝生物（603739）在互动平台回答投资者提问时表示，截至目前，公司业务 以国内市场为主，国内业务收入占比约为92%。公司海外市场主要包括美国、欧盟、菲律宾、埃及、巴 西等。其中，公司对欧盟市场的销售主要由境内主体直接向欧盟客户实现销售，相关收入占比很低。公 司将严格按照《上海证券交易所股票上市规则》等相关规定进行公告，及时履行信息披露义务，有关信 息请以公司在上海证券交易所网站披露的相关公告为准。 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-002 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 被担保人名称 | 本次担保金额 | | 实际为其提供的 担保余额（不含本 | | 是否在前期预计 | 本次担保是否有 反担保 | | --- | --- | --- | --- | --- | --- | --- | | | | | 次担保金额） | | 额度内 | | | 青岛蔚蓝生物集团 有限公司 | 4,000.00 | 万元 | 25,410.48 | 万元 | 是 | 否 | | 潍坊康地恩生物科 技有限公司 | 3,000.00 | 万元 | 7,153.98 | 万元 | 是 | 否 | | 青岛蔚蓝动物保健 集团有限公司 | 1,350.00 | 万元 | 4,980.00 | 万元 | 是 | 否 | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- ...

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Market Overview - The chemical products sector experienced a decline of 0.29% on January 13, with Qiaoyuan Co. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Top Performers - Huaheng Biological (688639) saw a significant increase of 13.79%, closing at 41.34 with a trading volume of 419,600 shares and a transaction value of 1.721 billion [1] - Chenghe Technology (688625) rose by 12.29%, closing at 62.32 with a trading volume of 109,000 shares and a transaction value of 672 million [1] - Kaisa Biological (688065) increased by 12.14%, closing at 62.24 with a trading volume of 177,800 shares [1] Underperformers - Qiaoyuan Co. (301286) fell by 8.67%, closing at 47.41 with a trading volume of 53,000 shares and a transaction value of 258 million [2] - Hangqing Co. (002430) decreased by 6.99%, closing at 32.06 with a trading volume of 311,600 shares [2] - Taihe Technology (300801) dropped by 6.72%, closing at 30.39 with a trading volume of 173,200 shares [2] Capital Flow - The chemical products sector saw a net outflow of 642 million from institutional investors and 357 million from retail investors, while retail investors had a net inflow of 999 million [2] - The capital flow data indicates a mixed sentiment among different investor types within the sector [2] Individual Stock Capital Flow - Duoliangduo (002407) had a net inflow of 224 million from institutional investors, while it experienced a net outflow of 1.09 billion from retail investors [3] - Wanhu Chemical (600309) saw a net inflow of 189 million from institutional investors, with a net outflow of 76.596 million from retail investors [3] - Yahua Group (002497) had a net inflow of 154 million from institutional investors, while retail investors experienced a net outflow of 17.488 million [3]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-001 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 作用与用途：用于预防鸡新城疫、H9 亚型禽流感、禽腺病毒病（I 群，4 型）、 鸡传染性法氏囊病。免疫产生期为 14 日，1～3 周龄雏鸡免疫期为 4 个月，3 周 龄及以上鸡免疫期为 6 个月。 用法与用量：肌肉或皮下注射。1～3 周龄雏鸡，每只 0.3ml；3 周龄及以上 鸡，每只 0.5ml。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛动 保国家工程技术研究中心有限公司、青岛蔚蓝动物保健集团有限公司与其他单位 联合申报的"鸡新城疫、禽流感（H9 亚型）、禽腺病毒病（I 群，4 型）、传染性 法氏囊病四联灭活疫苗（La Sota 株+TA 株+LC 株+VP2 蛋白）"为三类新兽药，并 于近日核发了《新兽药注册证书》（农业农村部公告第 987 号）。 一、新兽药 ...

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1 - The core point of the news is that Qingdao Weilan Biological Co., Ltd. experienced a stock price increase of 5.02%, reaching 15.06 CNY per share, with a total market capitalization of 3.811 billion CNY [1] - The company, established on February 23, 2005, specializes in the research, production, and sales of enzyme preparations, microecology, and animal health products [1] - The revenue composition of the company includes enzyme preparations at 36.63%, animal health products at 22.60%, other businesses at 21.75%, microecology at 17.27%, and others at 1.76% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund holds a position in Weilan Biological, with its Guotai Zhongzheng Livestock Breeding ETF (159865) increasing its holdings by 673,200 shares, totaling 2.1108 million shares, which represents 0.83% of the circulating shares [2] - The Guotai Zhongzheng Livestock Breeding ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY, and has recorded a year-to-date return of 0.4% [2] - The fund manager, Liang Xing, has a tenure of 9 years and 215 days, with the fund's total asset size at 30.617 billion CNY, achieving a best return of 1112.34% during the tenure [3]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-057 青岛蔚蓝生物股份有限公司 关于公司 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 12 月 26 日，公司召开第五届董事会第二十二次会议，审议通过了 《关于预计公司 2026 年度日常关联交易的议案》。根据《上海证券交易所股票上 市规则》《青岛蔚蓝生物股份有限公司章程》等的相关规定,公司无关联董事需对 本议案回避表决，所有董事一致同意通过该议案，且该议案无需提交公司股东会 审议。 （二）2025 年度日常关联交易预计和执行情况 2024 年 12 月 27 日，公司分别召开第五届董事会第十五次会议和第五届监 事会第九次会议，审议通过了《关于预计公司 2025 年度日常关联交易的议案》， 对公司 2025 年度日常关联交易情况进行了预计。2025 年度日常关联交易预计和 执行情况详见下表： 是否需要提交股东会审议：否 日常关联交易对上市公司的影响：本次日常关联交易预计为青岛蔚蓝生 物股份有 ...